



UNIVERSITY OF LEEDS

This is a repository copy of *Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study*.

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/98733/>

Version: Accepted Version

---

**Article:**

Coates, LC and Helliwell, P (2016) Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study. *Journal of Rheumatology*, 43 (2). pp. 356-361. ISSN 0315-162X

<https://doi.org/10.3899/jrheum.150614>

---

**Reuse**

Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

Table 1 – Baseline characteristics of the MTX population and total trial participants

Parameter	MTX population (n=188)	Total trial participants (n=206)
Male sex, n (%)	100 (53.2)	108 (52.4)
Age (years), median (IQR)	44.5 (37.0, 52.0)	45 (38, 53)
Ethnicity: Caucasian, n (%)	171 (91.0)	188 (91.3)
Number of swollen joints (0-66), median (IQR)	5.0 (3.0, 9.0)	5.0 (2.0, 9.0)
Number of tender joints (0-68), median (IQR)	9.0 (3.5, 19.0)	9.0 (4.0, 18.0)
CRP(mg/dl), median (IQR)	6.6 (5.0, 20.0)	6.7 (5.0, 18.2)
Rheumatoid factor negative, n (%)	177 (94.1)	195 (94.7)
CCP negative, n (%)	158 (84.0)	172 (83.5)
Early morning stiffness (EMS), n (%)	168 (89.4)	184 (89.3%)
EMS duration (hours), median (IQR) (patients with EMS)	1.0 (0.0, 2.0)	1.0 (0.5, 2.0)
Arthritis pattern, n (%) of patients		
Polyarthritis (≥5 joints)	135 (71.8)	146 (70.9)
Oligoarthritis (<5 joints)	53 (28.2)	60 (29.1)
DIP disease	41 (21.8)	45 (21.8)
Axial involvement	42 (22.3)	43 (20.9)
Arthritis mutilans	0 (0.0)	0 (0.0)
CASPAR criteria met (score ≥3), n (%)	172 (91.5)	188 (91.3)
CASPAR score ≥2, n (%)	184 (97.9)	202 (98.1)
Current psoriasis, n (%)	159 (84.6)	174 (84.5)
PASI score (all patients), median (IQR)	2.0 (0.6, 4.2)	1.9 (0.6, 4.2)

PASI score (condition at baseline), median (IQR)	2.6 (1.2, 4.7)	2.6 (1.2, 4.8)
Current enthesitis, n (%)	148 (78.7)	162 (78.6)
Enthesitis score (all patients), median (IQR)	2.0 (1.0, 6.0)	2.0 (1.0, 6.0)
Enthesitis score (condition at baseline), median (IQR)	4.0 (2.0, 7.0)	4.0 (2.0, 7.0)
Current dactylitis, n (%)	59 (31.4)	62 (30.1)
Dactylitis score (all patients), median (IQR)	0.0 (0.0, 15.8)	0.0 (0.0, 13.0)
Dactylitis score (condition at baseline), median (IQR)	38.0 (20.0, 105.0)	37.0 (19.0, 96.0)
Current nail disease, n (%)	117 (62.2)	124 (60.2)
mNAPSI score (all patients), median (IQR)	2.0 (0.0, 11.8)	2.0 (0.0, 10.0)
mNAPSI score (condition at baseline), median (IQR)	8.0 (2.0, 20.0)	8.0 (2.0, 19.0)

---

CASPAR – Classification of psoriatic arthritis, CCP – cyclic citrillinated peptide, CRP – C reactive protein, DIP – distal interphalangeal joint, mNAPSI – modified nail psoriasis severity index, PASI – psoriasis area and severity index

Table 2 – Outcomes at 12 weeks for those on methotrexate monotherapy

Outcome Measure	
ACR20, n (%)	69/169 (40.8)
Polyarthritis	56/121 (46.3)
Oligoarthritis	13/48 (27.1)
ACR50, n (%)	32/170 (18.8)
polyarthritis	23/121 (19.0)
oligoarthritis	9/49 (18.4)
ACR70, n (%)	15/174 (8.6)
polyarthritis	13/125 (10.4)
oligoarthritis	2/49 (4.1)
MDA, n (%)	39/174 (22.4)
polyarthritis	21/125 (16.8)
oligoarthritis	18/49 (36.7)
Change in PASDAS at 12 weeks, median (IQR)	-1.11 (-2.14, -0.40)
polyarthritis	-1.17 (-2.21, -0.35)
oligoarthritis	-1.03 (-1.65, -0.64)
PASDAS low disease activity $\leq 3.2$ , n (%)	63 (32.5)
polyarthritis	35 (25.0)
oligoarthritis	28 (51.9)
PASDAS good response, n (%)	35 (18.0)
Polyarthritis	24 (17.1)
Oligoarthritis	11 (20.4)
PASDAS moderate response, n (%)	76 (39.2)
Polyarthritis	53 (37.9)
Oligoarthritis	23 (42.6)

Change in tender joint count, median (IQR)	-2 (-6.25, 1)
Change in swollen joint count, median (IQR)	-3 (-6, -1)
PASI75, n (%)	43/158 (27.2)
Change in mNAPSI, median (IQR)	-2 (-8, 0)
Enthesitis all resolved, n (%)	38/148 (25.7)
Change in Leeds Enthesitis Index, median (IQR)	0 (-1, 0)
Change in IMPACT enthesitis score, median (IQR)	0 (-1, 0)
Change in MASES, median (IQR)	0 (-2, 1)
Dactylitis all resolved, n (%)	37/59 (62.7)
Change in Leeds dactylitis instrument basic score, median (IQR)	-59.7 (-157.4, -26.4)
Change in PsAQoL, median (IQR)	-1 (-4, 1)
Change in HAQ, median (IQR)	-0.1875 (-0.5, 0.0)
Reduction in HAQ $\geq$ MCID=0.35, n (%)	69/188 (36.7)
Change in patient global disease activity VAS, median (IQR)	-13.5 (-34, 1.75)
Change in patient pain VAS, median (IQR)	-13 (-32.25, 0)
Change in patient fatigue VAS, median (IQR)	-2 (-20, 8)

ACR – American College of Rheumatology, HAQ – health assessment questionnaire, IMPACT – Infliximab multinational psoriatic arthritis controlled trial, MASES –Maastricht ankylosing spondylitis enthesitis index, MDA – minimal disease activity, mNAPSI – modified nail psoriasis severity index, PASDAS – psoriatic arthritis disease activity score, PASI – psoriasis area and severity index, PsAQoL – Psoriatic arthritis quality of life, VAS – visual analogue score.

Table 3 – Adverse events reported in the MTX population in the first 12 weeks

Adverse Event description	Frequency	Definitely or probably related to MTX	AE severity			MTX held
			Mild	Mod	Severe	
Fatigue (n)	16	10	9	7	0	2
Hair loss/alopecia (n)	5	4	4	1	0	0
Nausea (n)	40	37	30	10	0	11
Vomiting (n)	2	1	1	1	0	1
Diarrhoea (n)	4	3	2	2	0	1
Abdominal/GI upset (n)	13	8	11	2	0	4
Mouth ulcer/cold sores (n)	7	4	3	2	2	3
Sore throat (n)	7	1	5	2	0	6
Cough (n)	4	0	2	2	0	1
Chest infection (n)	5	1	3	2	0	4
LRTI (n)	1	0	0	1	0	1
Shortness of breath (n)	2	0	0	2	0	1
Fever (n)	4	0	3	1	0	1
UTI (n)	1	0	1	0	0	0
Infection (other) (n)	7	0	4	3	0	2
Headache/migraine (n)	11	3	5	5	1	4
Mood disturbance/irritability (n)	4	1	4	0	0	1
Liver abnormalities (n)	30	20	25	5	0	18
Anaemia (n)	0	0	0	0	0	0
Neutropenia (n)	3	2	2	1	0	1

AE = adverse event, LRTI – lower respiratory tract infection, MTX = methotrexate, SAE = serious adverse event, UTI – urinary tract infection